FUTURE OF HEALTHCARE

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

GeneQuantum Healthcare | April 19, 2022

GeneQuantum and AIMEDBIO

GeneQuantum Healthcare Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic antibody drug conjugate (ADC).  Aimed Bio, a spin-off company from Samsung Medical Center, is focusing on developing innovative antibody-centric drugs for brain diseases with few treatment options. Additional details were not disclosed.

GeneQuantum focuses on next generation Antibody Drug Conjugate development. Taking advantage of the proprietary 'Ligase Dependent Conjugation' technology platform, which allows a site-specific conjugation of cytotoxins or other type of payloads to antibodies, the company has successfully developed a robust pipeline with more than 10 assets, with several at or approaching clinical stage. In addition to expanding the unique technology platform, the company has entered into a number of partnerships with domestic biotech/pharmaceutical companies and international partners. The growing number of partnerships speaks to the power of the GeneQuantum platform technology for not only improving key therapeutic characteristics of existing molecules, but also for creating new classes of molecules, ultimately increasing the number of available treatment options for patients worldwide.  GeneQuantum is excited about the significant potential of partnerships with business partners and will continue to expand its deal pipeline in the antibody drug conjugate and protein therapeutic market.

The collaborating ADC is a first-in-class asset with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect. The resulting ADC is expected to treat brain and other cancers with huge unmet needs.  

"As an innovative antibody+ company, we look for complementary partners to maximize value of our platform technology.  Aimed Bio not only has differentiated antibody acting on a unique target but also has deep knowledge and expertise in the field of brain tumor & CNS diseases. This collaboration is based on an excellent match between the two companies to generate a FIC ADC. Through close partnership, we are thrilled to bring revolutionary therapy for those patients without efficient treatment at this moment."  

Dr. Gang Qin, the Founder & Chairman, CEO of GeneQuantum

Dr. Dohyun Nam, the Founder & Chairman, CTO of Aimed Bio and internationally renowned neurosurgeon with 32 years of experience in brain tumor & CNS diseases commented: "Aimed Bio has been successfully expanding its R&D pipeline for the past 2 years, and I am pleased to start this collaboration with GeneQuantum. After evaluating the data, the linker-payload and conjugation technology GeneQuantum provides proved to be very safe and effective. With the best antibody and brain tumor expertise of Aimed Bio, I believe the collaborating ADC will bring a tremendous impact on the field. We look forward to initiating clinical trial as soon as possible."

About GeneQuantum Healthcare Co., Ltd.

GeneQuantum Healthcare Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics. The company is focused on the development of a next generation of bioconjugate therapeutics to meet the unmet medical needs of cancer patients globally. For more information, visit www.genequantum.com.

About AIMEDBIO Inc.

AIMEDBIO is a spin-off company from Samsung Medical Center established in August 2018. AIMEDBIO aims to provide therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases, to save patients' lives and improve patients' quality of life. Based on solid global networks with key opinion leaders in the field, an excellent research team with profound achievements, and R&D pipelines with an outstanding drug development platform, AIMEDBIO is an emerging leader for development of innovative therapeutics against diverse brain diseases.

Spotlight

In an accountable care organization (ACO), a network of providers shares the financial risk and responsibility for healthcare management and service delivery for a large group of patients.i Together, they work to find ways to improve population health and lower costs. For example, providers can better coordinate patient care to close gaps in care and avoid unnecessary tests and procedures.

Spotlight

In an accountable care organization (ACO), a network of providers shares the financial risk and responsibility for healthcare management and service delivery for a large group of patients.i Together, they work to find ways to improve population health and lower costs. For example, providers can better coordinate patient care to close gaps in care and avoid unnecessary tests and procedures.

Related News

HEALTH TECHNOLOGY

Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare

Google Cloud | July 18, 2022

Northwell Health, New York State's largest health care provider and private employer, and Google Cloud announced a collaboration to improve patient care, clinician experiences, and to help the health and hospital network operate more efficiently. The new alliance will be paramount in Northwell's effort to transform digital and connected experiences with the cloud and artificial intelligence (AI) to increase the efficiency of care and allow the health system more opportunities to better deliver equitable care in the communities it serves. Leveraging Google's advanced technology will give Northwell the ability to enhance experiences in digital scheduling, automate payer interactions and provide intelligent summarizations of medical information. In addition, Northwell will leverage Google Cloud's AI and machine learning (ML) capabilities for predictive insights to help with capacity planning and scheduling, and to identify risk indicators to help with early interventions. "Digital transformation is critical to our long-term goals of further advancing clinical excellence in our health system," said Michael Dowling, president and CEO, Northwell Health. "This partnership will help us deliver personalized experiences by safely and privately harnessing customers' data to enhance care, well-being, and equity in care for our patients." As part of this partnership, Northwell Health will leverage Google Cloud as its preferred cloud platform for infrastructure modernization, and to build an interoperable data platform with AI and ML capabilities. This includes contextual recommendations that equip nurses and clinicians with decision making support that goes beyond summarizing the information from different records, building relationships between the information to help support the right actions at the right time. "People want the same kind of seamless experiences and access to their healthcare that they have in other areas of their life, and healthcare providers need to meet these demands while also running the organization more efficiently. Northwell Health is taking the lead on innovation and interoperability to transform health and wellness for millions of New Yorkers." Joe Miles, managing director, Global Healthcare & Life Sciences Solutions for Google Cloud Privacy and security will be of the utmost importance in all aspects of this digital transformation. Through the implementation of Google Cloud's reliable infrastructure along with Northwell Health's layers of security, privacy controls and processes, the access and use of patient data will be appropriately protected. About Northwell Health Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 80,000 employees – 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. About Google Cloud Google Cloud accelerates every organization's ability to digitally transform its business. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology – all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.

Read More

HEALTH TECHNOLOGY

Vicarious Surgical Announces Center of Excellence Agreements with HCA Healthcare and UH Ventures to Advance System Design

Vicarious Surgical Inc. | July 08, 2022

Vicarious Surgical Inc. a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it has signed collaborative Center of Excellence agreements with both HCA Healthcare, one of the nation’s leading providers of healthcare services comprising 182 hospitals, and University Hospitals Ventures, the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with more than 20 hospitals, over 50 health centers, and over 200 physician offices in northern Ohio. As part of these agreements, HCA Healthcare and UH Ventures will each provide user input through their system physicians as the Company advances the design of its Vicarious Surgical Robot. Through these distinct collaborations, Vicarious Surgical will gain unique exposure to the detailed surgical workflows at each of these partners and incorporate direct surgeon and administrator feedback into its total product ecosystem to meet the needs of major US hospital systems. Additionally, clinical and human-centered design experts from both HCA Healthcare and UH will assist Vicarious Surgical to further enhance product design, helping ensure readiness for streamlined adoption upon FDA Approval. “Establishing our Center of Excellence model with two leading U.S. health systems offers significant validation of our system’s in-hospital potential and creates an incredible opportunity to integrate real-world surgeon experiences and feedback as we work toward our system’s finalization. These partnerships establish two powerful innovation conduits through which our team gains unprecedented access to understanding and addressing the complexities of surgical workflow and hospital integration while building commercial expertise. Meanwhile, our clinical partners – HCA Healthcare and University Hospitals – become the first health systems to access our minimally invasive surgical robot and directly influence its advancement. We could not be more excited to partner with two of the top institutions in the country as we progress on our path to improve surgery for patients, surgeons, hospitals, and payors.” Adam Sachs, CEO and co-founder of Vicarious Surgical “Our surgical and innovation teams are on the cutting edge of new care technologies designed to benefit patients,” said Dr. Joseph Sabik, Chairman, Department of Surgery at University Hospitals. “Collaborating with Vicarious Surgical on their Center of Excellence model for training and next generation surgical robotics provides our team a thrilling front row seat in the quest to improve the landscape for minimally-invasive surgery that enhances patient care and clinical outcomes.” “University Hospitals’ goal is to be the most trusted health care partner in Northeast Ohio,” explained Kendra Gardiner, Director of Product Strategy for UH Ventures. “As part of this strategy, UH is dedicated to accelerating discovery, innovation and translation of scientific breakthroughs that address unmet clinical and social needs to enhance the lives of our patients, our communities and the world. We also aim to be the partner of choice by creating and sharing value together. This new relationship with Vicarious Surgical is one example of how we are advancing this objective.” About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. HCA Healthcare subsidiary Health Insight Capital makes equity investments in early-stage companies that are selected to provide innovative solutions for use in health system operations and is an investor in Vicarious Surgical. Please click here to connect with HCA Healthcare on social media. About UH Ventures UH Ventures is the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with annual revenues in excess of $5.0 billion, more than 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. UH’s goal is to be the most trusted health care partner in Northeast Ohio and UH Ventures furthers this objective by shaping new products, services, experiences, and companies that improve the lives of patients and caregivers. To advance the UH mission, UH Ventures strives to support a diverse portfolio of value-adding opportunities in health care, enhance the distinct and unique capabilities of the system, and foster a culture of discovery, innovation, and entrepreneurship within UH and the larger community. For caregivers, UH Ventures provides the tools and resources needed to nurture, validate, and advance ideas sparked by day-to-day insights. For potential partners, UH Ventures seeks to be a dynamic living laboratory where both clinical and product insights can help accelerate emerging technologies tackling health care’s most pressing problems.

Read More

FUTURE OF HEALTHCARE

Exo® Acquires Medo AI to Make Medical Imaging as Easy as Snapping a Smartphone Photo

Exo | July 27, 2022

Exo a pioneering health information and medical devices company, announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use. By integrating Medo’s proprietary Sweep AI™ technology into its ultrasound platform, Exo will make ultrasound imaging more accessible to a wider range of caregivers. Ultrasound imaging is complex and requires specialized education and training. This limits the number of caregivers who can use point-of-care ultrasound to significantly improve patient care. Medo’s unique ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, allowing non-experts to conduct high-quality exams quickly and accurately. Medo’s two FDA-cleared AI algorithms, with more in development, combined with access to an extensive library of millions of ultrasound images and longitudinal health data bring a unique opportunity to speed point-of-care ultrasound adoption across the healthcare system — dramatically expanding early disease detection and accelerating the path to treatment. Medo also has strong partnerships with health systems worldwide, including top healthcare institutions in Asia and Canada, enabling global clinical validation and adoption. “This acquisition is about bringing unprecedented ease of use to ultrasound imaging — allowing caregivers to easily obtain and interpret ultrasound images,” said Sandeep Akkaraju, CEO and Founder of Exo. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.” "Exo’s powerful hardware and workflow technologies and Medo’s AI will dramatically reduce the challenges that have long held back the widespread adoption of point-of-care ultrasound. The ease of imaging and immediacy of diagnostic information we provide will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.” Dornoosh Zonoobi, CEO of Medo Exo recently launched Exo Works™, an intuitive point-of-care ultrasound workflow solution that streamlines documentation, billing, and quality assurance all from one platform, and will be commercializing a handheld ultrasound device that uses radically new technology to deliver powerful imaging at a fraction of the cost of a cart-based system. About Exo Exo is a health information and devices company. Exo believes everyone around the world should have access to high-quality, affordable and easy-to-use medical imaging. The company is on a mission to modernize medical imaging through its high-performance ultrasound platform and artificial intelligence. Exo’s goal is to enable healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes. This press release contains forward-looking statements regarding Exo’s future expectations, plans and prospects and are based on Exo’s current expectations and speak only as of the date hereof. Exo disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

Read More